Morgan Stanley on BridgeBio Oncology Therapeutics, In (BBOT): 'Strong efficacy and tolerability for BBO-8520'
Tweet Send to a Friend
Morgan Stanley analyst Sean Laaman reiterated an Overweight rating and $20.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
